<--- Back to Details
First PageDocument Content
Biology / Coagulation / MCFD2 / Thrombin / Mixing study / Haemophilia A / Factor X / Factor VIII / Factor V / Blood / Coagulation system / Anatomy
Date: 2014-04-22 11:47:00
Biology
Coagulation
MCFD2
Thrombin
Mixing study
Haemophilia A
Factor X
Factor VIII
Factor V
Blood
Coagulation system
Anatomy

Factor V deficiency: a concise review

Add to Reading List

Source URL: www.hemophilia.org

Download Document from Source Website

File Size: 60,38 KB

Share Document on Facebook

Similar Documents

REGULAR ARTICLE  CD4 T cells specific for factor VIII are present at high frequency in healthy donors and comprise na¨ıve and memory cells ´ ` 1

REGULAR ARTICLE CD4 T cells specific for factor VIII are present at high frequency in healthy donors and comprise na¨ıve and memory cells ´ ` 1

DocID: 1tX4g - View Document

News Releases  Global Home | CSL Behring US | CSL Plasma | All CSL Behring Web Sites  

News Releases Global Home | CSL Behring US | CSL Plasma | All CSL Behring Web Sites  

DocID: 1qHpD - View Document

For immediate release 26 May 2016 AFSTYLA® (rFVIII-Single Chain) – FDA approval CSL Limited (ASX:CSL; USOTC:CSLLY) - CSL today announced that the US Food and Drug Administration (FDA) has approved AFSTYLA® [Antihaemo

For immediate release 26 May 2016 AFSTYLA® (rFVIII-Single Chain) – FDA approval CSL Limited (ASX:CSL; USOTC:CSLLY) - CSL today announced that the US Food and Drug Administration (FDA) has approved AFSTYLA® [Antihaemo

DocID: 1oCE0 - View Document

13308 FT Factor VIII Plasma déficient

13308 FT Factor VIII Plasma déficient

DocID: 1odr2 - View Document

UPDATE: Baxalta’s BAX 855 Pivotal Data Published in Blood Shows  Potential to Provide Strong Bleed Prevention with Twice Weekly Dosing for Patients with Hemophilia A •

UPDATE: Baxalta’s BAX 855 Pivotal Data Published in Blood Shows Potential to Provide Strong Bleed Prevention with Twice Weekly Dosing for Patients with Hemophilia A •

DocID: 1kAcN - View Document